TY - JOUR
T1 - Fragment-to-Lead Medicinal Chemistry Publications in 2021
AU - Walsh, Louise
AU - Erlanson, Daniel A.
AU - de Esch, Iwan J.P.
AU - Jahnke, Wolfgang
AU - Woodhead, Andrew
AU - Wren, Ella
N1 - Publisher Copyright:
© 2023 American Chemical Society.
PY - 2023/1/26
Y1 - 2023/1/26
N2 - This Perspective is the seventh in an annual series that summarizes successful Fragment-to-Lead (F2L) case studies published in a given year. A tabulated summary of relevant articles published in 2021 is provided, and features such as target class, screening methods, and ligand efficiency are discussed, both for the 2021 examples and for the combined examples over the years 2015-2021. In addition, trends and new developments in the field are summarized. In particular, the use of structural information in fragment-based drug discovery is discussed.
AB - This Perspective is the seventh in an annual series that summarizes successful Fragment-to-Lead (F2L) case studies published in a given year. A tabulated summary of relevant articles published in 2021 is provided, and features such as target class, screening methods, and ligand efficiency are discussed, both for the 2021 examples and for the combined examples over the years 2015-2021. In addition, trends and new developments in the field are summarized. In particular, the use of structural information in fragment-based drug discovery is discussed.
UR - http://www.scopus.com/inward/record.url?scp=85146124026&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146124026&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.2c01827
DO - 10.1021/acs.jmedchem.2c01827
M3 - Review article
C2 - 36622056
AN - SCOPUS:85146124026
SN - 0022-2623
VL - 66
SP - 1137
EP - 1156
JO - Journal of medicinal chemistry
JF - Journal of medicinal chemistry
IS - 2
ER -
